Antibiotics and the developing intestinal microbiome, metabolome and inflammatory environment in a randomized trial of preterm infants

Abstract Antibiotic use in neonates can have detrimental effects on the developing gut microbiome, increasing the risk of morbidity. A majority of preterm neonates receive antibiotics after birth without clear evidence to guide this practice. Here microbiome, metabolomic, and immune marker results f...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jordan T. Russell, J. Lauren Ruoss, Diomel de la Cruz, Nan Li, Catalina Bazacliu, Laura Patton, Kelley Lobean McKinley, Timothy J. Garrett, Richard A. Polin, Eric W. Triplett, Josef Neu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/6f3a6371d2554c1597cec7f371a14a44
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6f3a6371d2554c1597cec7f371a14a44
record_format	dspace
spelling	oai:doaj.org-article:6f3a6371d2554c1597cec7f371a14a442021-12-02T13:56:56ZAntibiotics and the developing intestinal microbiome, metabolome and inflammatory environment in a randomized trial of preterm infants10.1038/s41598-021-80982-62045-2322https://doaj.org/article/6f3a6371d2554c1597cec7f371a14a442021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-80982-6https://doaj.org/toc/2045-2322Abstract Antibiotic use in neonates can have detrimental effects on the developing gut microbiome, increasing the risk of morbidity. A majority of preterm neonates receive antibiotics after birth without clear evidence to guide this practice. Here microbiome, metabolomic, and immune marker results from the routine early antibiotic use in symptomatic preterm Neonates (REASON) study are presented. The REASON study is the first trial to randomize symptomatic preterm neonates to receive or not receive antibiotics in the first 48 h after birth. Using 16S rRNA sequencing of stool samples collected longitudinally for 91 neonates, the effect of such antibiotic use on microbiome diversity is assessed. The results illustrate that type of nutrition shapes the early infant gut microbiome. By integrating data for the gut microbiome, stool metabolites, stool immune markers, and inferred metabolic pathways, an association was discovered between Veillonella and the neurotransmitter gamma-aminobutyric acid (GABA). These results suggest early antibiotic use may impact the gut-brain axis with the potential for consequences in early life development, a finding that needs to be validated in a larger cohort. Trial Registration This project is registered at clinicaltrials.gov under the name “Antibiotic ‘Dysbiosis’ in Preterm Infants” with trial number NCT02784821.Jordan T. RussellJ. Lauren RuossDiomel de la CruzNan LiCatalina BazacliuLaura PattonKelley Lobean McKinleyTimothy J. GarrettRichard A. PolinEric W. TriplettJosef NeuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-16 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jordan T. Russell J. Lauren Ruoss Diomel de la Cruz Nan Li Catalina Bazacliu Laura Patton Kelley Lobean McKinley Timothy J. Garrett Richard A. Polin Eric W. Triplett Josef Neu Antibiotics and the developing intestinal microbiome, metabolome and inflammatory environment in a randomized trial of preterm infants
description	Abstract Antibiotic use in neonates can have detrimental effects on the developing gut microbiome, increasing the risk of morbidity. A majority of preterm neonates receive antibiotics after birth without clear evidence to guide this practice. Here microbiome, metabolomic, and immune marker results from the routine early antibiotic use in symptomatic preterm Neonates (REASON) study are presented. The REASON study is the first trial to randomize symptomatic preterm neonates to receive or not receive antibiotics in the first 48 h after birth. Using 16S rRNA sequencing of stool samples collected longitudinally for 91 neonates, the effect of such antibiotic use on microbiome diversity is assessed. The results illustrate that type of nutrition shapes the early infant gut microbiome. By integrating data for the gut microbiome, stool metabolites, stool immune markers, and inferred metabolic pathways, an association was discovered between Veillonella and the neurotransmitter gamma-aminobutyric acid (GABA). These results suggest early antibiotic use may impact the gut-brain axis with the potential for consequences in early life development, a finding that needs to be validated in a larger cohort. Trial Registration This project is registered at clinicaltrials.gov under the name “Antibiotic ‘Dysbiosis’ in Preterm Infants” with trial number NCT02784821.
format	article
author	Jordan T. Russell J. Lauren Ruoss Diomel de la Cruz Nan Li Catalina Bazacliu Laura Patton Kelley Lobean McKinley Timothy J. Garrett Richard A. Polin Eric W. Triplett Josef Neu
author_facet	Jordan T. Russell J. Lauren Ruoss Diomel de la Cruz Nan Li Catalina Bazacliu Laura Patton Kelley Lobean McKinley Timothy J. Garrett Richard A. Polin Eric W. Triplett Josef Neu
author_sort	Jordan T. Russell
title	Antibiotics and the developing intestinal microbiome, metabolome and inflammatory environment in a randomized trial of preterm infants
title_short	Antibiotics and the developing intestinal microbiome, metabolome and inflammatory environment in a randomized trial of preterm infants
title_full	Antibiotics and the developing intestinal microbiome, metabolome and inflammatory environment in a randomized trial of preterm infants
title_fullStr	Antibiotics and the developing intestinal microbiome, metabolome and inflammatory environment in a randomized trial of preterm infants
title_full_unstemmed	Antibiotics and the developing intestinal microbiome, metabolome and inflammatory environment in a randomized trial of preterm infants
title_sort	antibiotics and the developing intestinal microbiome, metabolome and inflammatory environment in a randomized trial of preterm infants
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/6f3a6371d2554c1597cec7f371a14a44
work_keys_str_mv	AT jordantrussell antibioticsandthedevelopingintestinalmicrobiomemetabolomeandinflammatoryenvironmentinarandomizedtrialofpreterminfants AT jlaurenruoss antibioticsandthedevelopingintestinalmicrobiomemetabolomeandinflammatoryenvironmentinarandomizedtrialofpreterminfants AT diomeldelacruz antibioticsandthedevelopingintestinalmicrobiomemetabolomeandinflammatoryenvironmentinarandomizedtrialofpreterminfants AT nanli antibioticsandthedevelopingintestinalmicrobiomemetabolomeandinflammatoryenvironmentinarandomizedtrialofpreterminfants AT catalinabazacliu antibioticsandthedevelopingintestinalmicrobiomemetabolomeandinflammatoryenvironmentinarandomizedtrialofpreterminfants AT laurapatton antibioticsandthedevelopingintestinalmicrobiomemetabolomeandinflammatoryenvironmentinarandomizedtrialofpreterminfants AT kelleylobeanmckinley antibioticsandthedevelopingintestinalmicrobiomemetabolomeandinflammatoryenvironmentinarandomizedtrialofpreterminfants AT timothyjgarrett antibioticsandthedevelopingintestinalmicrobiomemetabolomeandinflammatoryenvironmentinarandomizedtrialofpreterminfants AT richardapolin antibioticsandthedevelopingintestinalmicrobiomemetabolomeandinflammatoryenvironmentinarandomizedtrialofpreterminfants AT ericwtriplett antibioticsandthedevelopingintestinalmicrobiomemetabolomeandinflammatoryenvironmentinarandomizedtrialofpreterminfants AT josefneu antibioticsandthedevelopingintestinalmicrobiomemetabolomeandinflammatoryenvironmentinarandomizedtrialofpreterminfants
_version_	1718392329027452928

Antibiotics and the developing intestinal microbiome, metabolome and inflammatory environment in a randomized trial of preterm infants

Ejemplares similares